PMLRARα binds to Fas and suppresses Fas-mediated apoptosis through recruiting c-FLIP in vivo

Blood

Volumn 118, Issue 11, 2011, Pages 3107-3118

  Tao, Rong Hua ^a   Berkova, Zuzana ^a   Wise, Jillian F ^a   Rezaeian, Abdol Hossein ^a   Daniluk, Urszula ^a   Ao, Xue ^a   Hawke, David H ^a   Karp, Judith E ^b   Lin, Hui Kuan ^a   Molldrem, Jeffrey J ^a   Samaniego, Felipe ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIBODY; FAS ANTIGEN; FLICE INHIBITORY PROTEIN; PROCASPASE 8; PROMYELOCYTIC LEUKEMIA PROTEIN; RETINOIC ACID RECEPTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL STRAIN U937; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; MASS SPECTROMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN PROTEIN INTERACTION;

EID: 80052956691     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-04-349670     Document Type: Article

References (49)

1. Takahashi Y, Lallemand-Breitenbach V, Zhu J, de The H. PML nuclear bodies and apoptosis. Oncogene. 2004;23(16):2819-2824. (Pubitemid 38659528)
2. Wang X, DeFrances MC, Dai Y, et al. A mechanism of cell survival: sequestration of Fas by the HGF receptor Met. Mol Cell. 2002;9(2):411-421. (Pubitemid 34195565)
3. Wang S, Maeng H, Young DP, et al. K1 protein of human herpesvirus 8 suppresses lymphoma cell Fas-mediated apoptosis. Blood. 2007;109(5): 2174-2182. (Pubitemid 46348220)
4. Berkova Z, Tao RH, Samaniego F. Milatuzumab-a promising new immunotherapuetic agent. Expert Opin Investig Drugs. 2009;19(1):141-149.
5. Muller M, Scaffidi CA, Galle PR, Stremmel W, Krammer PH. The role of p53 and the CD95 (APO-1/Fas) death system in chemotherapy-induced apoptosis. Eur Cytokine Netw. 1998;9(4): 685-686. (Pubitemid 29033938)
6. Fulda S, Meyer E, Friesen C, Susin SA, Kroemer G, Debatin KM. Cell type specific involvement of death receptor and mitochondrial pathways in drug-induced apoptosis. Oncogene. 2001;20(9): 1063-1075. (Pubitemid 32238855)
7. Fulda S, Scaffidi C, Pietsch T, Krammer PH, Peter ME, Debatin KM. Activation of the CD95 (APO-1/Fas) pathway in drug- and gamma-irradiation- induced apoptosis of brain tumor cells. Cell Death Differ. 1998;5(10):884-893. (Pubitemid 28484399)
8. Janin A, Deschaumes C, Daneshpouy M, et al. CD95 engagement induces disseminated endothelial cell apoptosis in vivo: immunopathologic implications. Blood. 2002;99(8):2940-2947. (Pubitemid 34525384)
9. Gurrieri C, Capodieci P, Bernardi R, et al. Loss of the tumor suppressor PML in human cancers of multiple histologic origins. J Natl Cancer Inst. 2004;96(4):269-279. (Pubitemid 38256272)
10. de The H, Lavau C, Marchio A, Chomienne C, Degos L, Dejean A. The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell. 1991;66(4):675-684. (Pubitemid 121001703)
11. Kakizuka A, Miller WH Jr, Umesono K, et al. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell. 1991;66(4):663-674. (Pubitemid 121001702)
12. Parmar S, Tallman MS. Acute promyelocytic leukaemia: a review. Expert Opin Pharmacother. 2003;4(8):1379-1392. (Pubitemid 36949684)
13. Wang ZG, Ruggero D, Ronchetti S, et al. PML is essential for multiple apoptotic pathways. Nat Genet. 1998;20(3):266-272. (Pubitemid 28507671)
14. Grignani F, Ferrucci PF, Testa U, et al. The acute promyelocytic leukemia-specific PML-RARalpha fusion protein inhibits differentiation and promotes survival of myeloid precursor cells. Cell. 1993;74(3):423-431. (Pubitemid 23244608)
15. Guo Y, Dolinko AV, Chinyengetere F, et al. Blockade of the ubiquitin protease UBP43 destabilizes transcription factor PML/RARalpha and inhibits the growth of acute promyelocytic leukemia. Cancer Res. 2010;70(23):9875-9885.
16. Ariumi Y, Ego T, Kaida A, Matsumoto M, Pandolfi PP, Shimotohno K. Distinct nuclear body components, PML and SMRT, regulate the trans-acting function of HTLV-1 Tax oncoprotein. Oncogene. 2003;22(11):1611-1619. (Pubitemid 36408176)
17. Berkova Z, Wang S, Wise JF, Maeng H, Ji Y, Samaniego F. Mechanism of Fas signaling regulation by human herpesvirus 8 K1 oncoprotein. J Natl Cancer Inst. 2009;101(6):399-411.
18. Kamitani T, Nguyen HP, Kito K, Fukuda-Kamitani T, Yeh ET. Covalent modification of PML by the sentrin family of ubiquitin-like proteins. J Biol Chem. 1998;273(6):3117-3120. (Pubitemid 28109713)
19. Tao RH, Kawate H, Wu Y, et al. Testicular zinc finger protein recruits histone deacetylase 2 and suppresses the transactivation function and intranuclear foci formation of agonist-bound androgen receptor competitively with TIF2. Mol Cell Endocrinol. 2006;247(1-2):150-165. (Pubitemid 43277719)
20. Tao RH, Maruyama IN. Ligand-induced activation of preformed inactive EGF/ErbB receptor homoand heterodimers: a model for EGF/ErbB receptors. FASEB J. 2008;22(1):1054-1054.
21. Tao RH, Maruyama IN. All the EGF(ErbB) receptors have preformed homo- and heterodimeric structures in living cells. J Cell Sci. 2008;121 (Pt 19):3207-3217.
22. Liu F, Song Y, Liu D. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther. 1999;6(7):1258-1266. (Pubitemid 29359019)
23. Cardier JE, Schulte T, Kammer H, Kwak J, Cardier M. Fas (CD95, APO-1) antigen expression and function in murine liver endothelial cells: implications for the regulation of apoptosis in liver endothelial cells. FASEB J. 1999;13(14):1950-1960. (Pubitemid 29517625)
24. van Blitterswijk WJ, Klarenbeek JB, van der Luit AH, Alderliesten MC, van Lummel M, Verheij M. Fas/ CD95 down-regulation in lymphoma cells through acquired alkyllysophospholipid resistance: partial role of associated sphingomyelin deficiency. Biochem J. 2009;425(1):225-234.
25. Yin XM, Wang K, Gross A, et al. Bid-deficient mice are resistant to Fas-induced hepatocellular apoptosis. Nature. 1999;400(6747):886-891. (Pubitemid 29406726)
26. Schungel S, Buitrago-Molina LE, Nalapareddy P, et al. The strength of the Fas ligand signal determines whether hepatocytes act as type 1 or type 2 cells in murine livers. Hepatology. 2009;50(5): 1558-1566.
27. Zhong S, Salomoni P, Pandolfi PP. The transcriptional role of PML and the nuclear body. Nat Cell Biol. 2000;2(5):E85-90.
28. Bernardi R, Pandolfi PP. Role of PML and the PML-nuclear body in the control of programmed cell death. Oncogene. 2003;22(56):9048-9057.
29. Dellaire G, Bazett-Jones DP. PML nuclear bodies: dynamic sensors of DNA damage and cellular stress. Bioessays. 2004;26(9):963-977. (Pubitemid 39273070)
30. Jensen K, Shiels C, Freemont PS. PML protein isoforms and the RBCC/TRIM motif. Oncogene. 2001;20(49):7223-7233. (Pubitemid 33105011)
31. Tussie-Luna MI, Rozo L, Roy AL. Pro-proliferative function of the long isoform of PML-RARalpha involved in acute promyelocytic leukemia. Oncogene. 2006;25(24):3375-3386. (Pubitemid 43877041)
32. Early E, Moore MA, Kakizuka A, et al. Transgenic expression of PML/RARalpha impairs myelopoiesis. Proc Natl Acad Sci U S A. 1996;93(15): 7900-7904. (Pubitemid 26277136)
33. Guo A, Salomoni P, Luo J, et al. The function of PML in p53-dependent apoptosis. Nat Cell Biol. 2000;2(10):730-736.
34. Sieben M, Herzer K, Zeidler M, et al. Killing of p53-deficient hepatoma cells by parvovirus H-1 and chemotherapeutics requires promyelocytic leukemia protein. World J Gastroenterol. 2008;14(24):3819-3828.
35. Lin HK, Bergmann S, Pandolfi PP. Cytoplasmic PML function in TGF-beta signalling. Nature. 2004;431(7005):205-211.
36. Giorgi C, Ito K, Lin HK, et al. PML regulates apoptosis at endoplasmic reticulum by modulating calcium release. Science. 2010;330(6008):1247-1251.
37. Bernardi R, Pandolfi PP. Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies. Nat Rev Mol Cell Biol. 2007;8(12):1006-1016. (Pubitemid 350174636)
38. Mitsiades CS, Poulaki V, Fanourakis G, et al. Fas signaling in thyroid carcinomas is diverted from apoptosis to proliferation. Clin Cancer Res. 2006; 12(12):3705-3712. (Pubitemid 44000250)
39. Zhu J, Zhou J, Peres L, et al. A sumoylation site in PML/RARA is essential for leukemic transformation. Cancer Cell. 2005;7(2):143-153. (Pubitemid 40248340)
40. Testa U, Grignani F, Samoggia P, et al. The PML/RARalpha fusion protein inhibits tumor necrosis factor-alpha-induced apoptosis in U937 cells and acute promyelocytic leukemia blasts. J Clin Invest. 1998;101(10):2278-2289. (Pubitemid 28244112)
41. Budd RC, Yeh WC, Tschopp J. cFLIP regulation of lymphocyte activation and development. Nat Rev Immunol. 2006;6(3):196-204. (Pubitemid 43290989)
42. Day TW, Huang S, Safa AR. c-FLIP knockdown induces ligand-independent DR5-, FADD-, caspase-8-, and caspase-9-dependent apoptosis in breast cancer cells. Biochem Pharmacol. 2008; 76(12):1694-1704.
43. Müller M, Strand S, Hug H, et al. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J Clin Invest. 1997;99(3):403-413. (Pubitemid 27414797)
44. Gurrieri C, Nafa K, Merghoub T, et al. Mutations of the PML tumor suppressor gene in acute promyelocytic leukemia. Blood. 2004;103(6):2358-2362. (Pubitemid 38326258)
45. Shah SJ, Blumen S, Pitha-Rowe I, et al. UBE1L represses PML/RAR{alpha} by targeting the PML domain for ISG15ylation. Mol Cancer Ther. 2008; 7(4):905-914. (Pubitemid 351551044)
46. Zhang XW, Yan XJ, Zhou ZR, et al. Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. Science. 2010;328(5975):240-243.
47. Kitareewan S, Pitha-Rowe I, Sekula D, et al. UBE1L is a retinoid target that triggers PML/RARalpha degradation and apoptosis in acute promyelocytic leukemia. Proc Natl Acad Sci U SA. 2002;99(6):3806-3811. (Pubitemid 34252187)
48. Zhu J, Okumura H, Ohtake S, Nakamura S, Nakao S. Arsenic trioxide induces apoptosis in leukemia/lymphoma cell lines via the CD95/CD95L system. Oncol Rep. 2003;10(3):705-709.
49. Wang DH, Wei HL, Zhao HS, Hao CY, Min ZH, Liu JM. Arsenic trioxide overcomes apoptosis inhibition in K562/ADM cells by regulating vital components in apoptotic pathway. Pharmacol Res. 2005;52(5):376-385.